Acelyrin Inc (SLRN)

May 13, 2025, 1:00 PM EDT - 23 days ago

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 6, 2025, 4:30 PM EDT - 4 weeks ago

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

May 1, 2025, 1:30 PM EDT - 5 weeks ago

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Apr 16, 2025, 5:31 PM EDT - 7 weeks ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

ALMS

Mar 13, 2025, 7:00 AM EDT - 3 months ago

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

Mar 4, 2025, 9:01 AM EST - 3 months ago

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:00 AM EST - 3 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

ALMS

Feb 20, 2025, 9:00 PM EST - 3 months ago

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Feb 7, 2025, 3:22 PM EST - 4 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

ALMS

Jan 7, 2025, 8:42 AM EST - 5 months ago

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

TSLA

Jan 6, 2025, 4:00 PM EST - 5 months ago

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Jan 2, 2025, 8:00 PM EST - 5 months ago

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

Dec 10, 2024, 4:30 PM EST - 6 months ago

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Nov 13, 2024, 9:38 PM EST - 7 months ago

Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:00 PM EST - 7 months ago

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 6, 2024, 4:00 PM EST - 7 months ago

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

Sep 20, 2024, 4:33 PM EDT - 9 months ago

Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch

Sep 19, 2024, 7:00 AM EDT - 9 months ago

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

Aug 22, 2024, 7:00 AM EDT - 10 months ago

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

Aug 14, 2024, 12:29 PM EDT - 10 months ago

Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep

Aug 13, 2024, 10:32 PM EDT - 10 months ago

Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:30 PM EDT - 10 months ago

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

May 29, 2024, 7:00 AM EDT - 1 year ago

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

May 9, 2024, 8:01 AM EDT - 1 year ago

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Apr 29, 2024, 4:05 PM EDT - 1 year ago

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

Mar 28, 2024, 4:05 PM EDT - 1 year ago

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

Mar 11, 2024, 8:02 AM EDT - 1 year ago

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Mar 11, 2024, 8:00 AM EDT - 1 year ago

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

Feb 15, 2024, 4:05 PM EST - 1 year ago

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

Jan 16, 2024, 12:05 AM EST - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Jan 15, 2024, 5:00 AM EST - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm

Jan 11, 2024, 1:30 PM EST - 1 year ago

ACELYRIN INVESTOR DEADLINE APPROACHING

Jan 9, 2024, 7:00 AM EST - 1 year ago

FINAL DEADLINE THIS MONTH: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Jan 8, 2024, 4:00 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Jan 4, 2024, 11:00 AM EST - 1 year ago

ACELYRIN INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

Dec 29, 2023, 3:30 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Dec 28, 2023, 9:45 AM EST - 1 year ago

ACELYRIN INVESTOR DEADLINE APPROACHING : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Dec 20, 2023, 4:30 PM EST - 1 year ago

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

Dec 19, 2023, 5:30 AM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Dec 11, 2023, 6:30 AM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Dec 7, 2023, 8:00 AM EST - 1 year ago

Acelyrin Looks Interesting Before PsA Data In Q1

Dec 6, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm